Chronic Itch

In this video, Raj Chovatiya, MD, PhD, discussed results of a study following patients with atopic dermatitis who were on lebrikizumab for 3 continuous years.

Nemolizumab monotherapy improved the signs and symptoms of prurigo nodularis, according to new data published in JAMA Dermatology.

In a phone-led qualitative study, 21 patients with prurigo nodularis expressed that their disease negatively impacts many aspects of their physical, psychological and social well-being.

Moderate to severe pruritus remains a chronic problem in patients on maintenance hemodialysis that can reduce overall quality of life, according to recently published data.

Prevalence of prurigo nodularis is higher than previously estimated and is associated with many comorbidities, according to a study.

A greater proportion of patients treated with nemolizumab for prurigo nodularis achieved an itch-free state than those treated with placebo, according to phase 3 results presented at the 25th World Congress of Dermatology.

Itch intensity was reduced in patients with chronic kidney disease and moderate to severe pruritus who were treated with oral difelikefalin, according to a study.

NEW ORLEANS — Symptoms of prurigo nodularis were significantly improved after 16 weeks of monotherapy with nemolizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.